The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

  • End date
    Dec 31, 2028
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 23 February 2022
neutrophil count
tumor thrombosis


To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.

Condition Hepatocellular Carcinoma
Treatment TAI
Clinical Study IdentifierNCT03368651
SponsorSun Yat-sen University
Last Modified on23 February 2022


Yes No Not Sure

Inclusion Criteria

older than 18 years old and younger than 75 years
proven hepatocellular carcinoma according patological examination or EASL/AASLD diagnostic criteria
not previous treated for tumor
estimated tumor and tumor thrombosis could be removed en bloc in operation
no distant metastasis
the lab test could meet: neutrophil count2.0109/L; hemoglobin100g/L; platelet count75109/L; serum albumin35g/L; total bilirubin<2-times upper limit of normal; ALT<3-times upper limit of normal; AST<3-times upper limit of normal; serum creatine<1.5-times upper limit of normal; PTupper limit of normal plus 4 seconds; INR2.2
sign up consent

Exclusion Criteria

cannot tolerate TAI or surgery
distant metastasis exits
known history of other malignancy
be allergic to related drugs
underwent organ transplantation before
be treated before (interferon included)
known history of HIV infection
known history of drug or alcohol abuse
have GI hemorrhage or cardiac/brain vascular events within 30 days
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note